Cargando…

Out-of-Pocket Costs for Colonoscopy After Noninvasive Colorectal Cancer Screening Among US Adults With Commercial and Medicare Insurance

This economic evaluation examines whether adult patients in the US who have commercial or Medicare insurance pay out-of-pocket costs associated with follow-up colonoscopy within 6 months of a noninvasive stool-based test.

Detalles Bibliográficos
Autores principales:	Fendrick, A. Mark, Princic, Nicole, Miller-Wilson, Lesley-Ann, Wilson, Kathleen, Limburg, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640889/ https://www.ncbi.nlm.nih.gov/pubmed/34854909 http://dx.doi.org/10.1001/jamanetworkopen.2021.36798

Ejemplares similares

Out-of-Pocket Costs for Colposcopy Among Commercially Insured Women From 2006 to 2019
por: Fendrick, A. Mark, et al.
Publicado: (2022)

Monthly Cost-Sharing Limits and Out-of-pocket Costs for Commercially Insured Patients in the US
por: Shafer, Paul R., et al.
Publicado: (2022)

Utilization of a Colorectal Cancer Screening Test Among Individuals With Average Risk
por: Fisher, Deborah A., et al.
Publicado: (2021)

Out-of-Pocket Costs of Diagnostic Breast Imaging Services After Screening Mammography Among Commercially Insured Women From 2010 to 2017
por: Lowry, Kathryn P., et al.
Publicado: (2021)

Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance
por: DiStefano, Michael J., et al.
Publicado: (2023)

Cost-Effectiveness of Waiving Coinsurance for Follow-Up Colonoscopy after a Positive Stool-Based Colorectal Screening Test in a Medicare Population
por: Fendrick, A. Mark, et al.
Publicado: (2022)

Impact of Eliminating Cost-Sharing by Medicare Beneficiaries for Follow-Up Colonoscopy After a Positive Stool-based Colorectal Cancer Screening Test
por: Fendrick, A. Mark, et al.
Publicado: (2023)

Impact of Out-of-Pocket Cost on Herpes Zoster Vaccine Uptake: An Observational Study in a Medicare Managed Care Population
por: Tao, Zhuliang, et al.
Publicado: (2018)

Out-of-Pocket Costs and Prescription Filling Behavior of Commercially Insured Individuals With Chronic Obstructive Pulmonary Disease
por: Patel, Bhavin, et al.
Publicado: (2022)

16. Attributable Mortality, Healthcare Costs and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees
por: Yu, Holly, et al.
Publicado: (2021)

Progressivity of out-of-pocket costs for Medicare-subsidised services and medicines in Australia.
por: Di Law, Hsei, et al.
Publicado: (2022)

Incidence, Attributable Mortality, and Healthcare and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees
por: Yu, Holly, et al.
Publicado: (2022)

Costs and repeat rates associated with colonoscopy observed in medical claims for commercial and Medicare populations
por: Pyenson, Bruce, et al.
Publicado: (2014)

Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D
por: Tseng, Chien-Wen, et al.
Publicado: (2020)

Evaluation of Medicare Coverage and Estimated Out-of-Pocket Costs for Generic Abiraterone Products
por: Gupta, Arjun, et al.
Publicado: (2022)

Comparison of Screening Colonoscopy Rates After Positive Noninvasive Testing for Colorectal Cancer in States With and Without Cost-Sharing
por: Barthold, Douglas, et al.
Publicado: (2022)

Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US
por: Sandhaus, Robert, et al.
Publicado: (2020)

Out-of-Pocket Spending for Influenza Hospitalizations in Medicare Advantage
por: Chua, Kao-Ping, et al.
Publicado: (2021)

Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers
por: Lin, Dora H., et al.
Publicado: (2018)

Trends in Pricing and Out-of-Pocket Spending on Entecavir Among Commercially Insured Patients, 2014-2018
por: Alpern, Jonathan D., et al.
Publicado: (2022)

Out-of-pocket health spending among Medicare beneficiaries: Which chronic diseases are most costly?
por: Fong, Joelle H.
Publicado: (2019)

Adherence to fecal immunochemical test screening among adults at average risk for colorectal cancer
por: Fisher, Deborah A., et al.
Publicado: (2021)

More surgery in December among US patients with commercial insurance is offset by unrelated but lesser surgery among patients with Medicare insurance
por: Dexter, Franklin, et al.
Publicado: (2022)

Unintended Consequences of Increased Out-of-Pocket Costs During Medicare Coverage Gap on Anticoagulant Discontinuation and Stroke
por: Salam, Tabassum, et al.
Publicado: (2023)

Out-of-Pocket Costs of Treatment Among Employer-Insured Women With Invasive Breast Cancer
por: Hager, Audrey, et al.
Publicado: (2023)

Billing the Insured: An Assessment of Out-of-Pocket Payment by Insured Patients in Ghana
por: Amporfu, Eugenia, et al.
Publicado: (2023)

Life-years gained resulting from screening colonoscopy compared with follow-up colonoscopy after a positive stool-based colorectal screening test
por: Mark Fendrick, A., et al.
Publicado: (2022)

Assessment of Out-of-Pocket Costs for Robotic Cancer Surgery in US Adults
por: Nabi, Junaid, et al.
Publicado: (2020)

Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009
por: Dalal, Anand A, et al.
Publicado: (2011)

Association of Out-of-Pocket Spending With Insulin Adherence in Medicare Part D
por: Trish, Erin, et al.
Publicado: (2021)

Spending and Out-of-Pocket Prices for Brand-Name Drugs Among Commercially Insured Individuals in Massachusetts, 2015-2017
por: Aaron, Micah B., et al.
Publicado: (2021)

ENTERING MEDICARE ADVANTAGE FROM EMPLOYER-SPONSORED PLANS: CHANGE IN OUT-OF-POCKET COSTS AND UTILIZATION AT AGE 65
por: Hames, Alexandra Glynn, et al.
Publicado: (2022)

Costs of pediatric liver transplantation among commercially insured and Medicaid-insured patients with cholestasis in the US
por: Miloh, Tamir, et al.
Publicado: (2023)

Use of Telemedicine for Buprenorphine Inductions in Patients With Commercial Insurance or Medicare Advantage
por: Barsky, Benjamin A., et al.
Publicado: (2022)

Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population
por: Wang, Ching-Yu, et al.
Publicado: (2022)

The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, medicare, and medicaid
por: Jacobson, Jed J, et al.
Publicado: (2012)

Medical Claim Cost Impact of Improved Diabetes Control for Medicare and Commercially Insured Patients with Type 2 Diabetes
por: Fitch, Kathryn, et al.
Publicado: (2013)

Patterns of Comorbidity and Multimorbidity Among Patients With Multiple Sclerosis in a Large US Commercially Insured and Medicare Advantage Population
por: Dai, Dingwei, et al.
Publicado: (2022)

Trends in Out-of-Pocket Costs for Naloxone by Drug Brand and Payer in the US, 2010-2018
por: Peet, Evan D., et al.
Publicado: (2022)

Cost of Treatment in a US Commercially Insured, HIV-1–Infected Population
por: Solem, Caitlyn T., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2g4nig2q4jfdq9950et2thrfvd